New antitumor vaccines control melanoma growth in preclinical models

New antitumor vaccines control melanoma growth in preclinical models

New antitumor vaccines control melanoma growth in preclinical models

Combining their expertise in protein engineering and synthetic DNA technology, scientists at The Wistar Institute successfully delivered nanoparticle antitumor vaccines that stimulated robust CD8 T cell immunity and controlled melanoma growth in preclinical models.